SEAGEN

📅 Upcoming

🕒 Recent(90d)

News

• FDA review docs spark Revolution sell-off; Zealand diabetes data underwhelm analysts
  The new disclosure suggested Rasonque might not be as broadly effective as previously thought. Elsewhere, Ultragenyx got a much-needed cash infusion and TCGX started a China-focused fund.
  biopharma_dive · 22d ago
• Deep Dive: How AI is now essential in biopharma
  As Big Pharma adds AI technology to bolster drug development, a cadre of new, upstart biotechs are pushing drug discovery to new heights.
  biospace · 1mo ago
• Pfizer punts Seagen ADC, further muddying value of the $43B buyout
  The co-development deal comes after Pfizer reported a late-stage failure for a Seagen asset and the discontinuation of another investigational therapy developed by the company as a subsidiary of th…
  biospace · 1mo ago
• Pfizer shares ADC rights with Medicus; RevMed updates lung cancer data
  Plus, news about Novartis. 🤝 Pfizer turns over ADC: The New York pharma is giving Medicus Pharma co-development rights to a CD228-targeted antibody-drug conjugate known as PF-08046031, a Seagen-de…
  endpoints · 1mo ago
• Pfizer offloads scrapped Seagen ADC to Medicus Pharma in up to $1B+ deal
  Pfizer has found a new home for an antibody-drug conjugate it acquired in its $43 billion Seagen buyout and dropped earlier this year.
  fiercebiotech · 1mo ago
• Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch
  Some analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.
  biopharma_dive · 2mo ago
• Pfizer CEO defends $7B bolt-on M&A strategy as peers rush to buy
  Asked on a second quarter earnings call if Pfizer could direct more money to M&A amid a feeding frenzy across the pharma industry, CEO Albert Bourla defended his strategy.
  biospace · 2mo ago
• Pfizer expands multibillion-dollar cost-cutting plan
  Hatched three years ago, the restructuring is now expected to deliver $1 billion in new cost reductions and save Pfizer another $1.5 billion by streamlining drug production.
  biopharma_dive · 2mo ago
• Make or break: Commercial hires critical for success
  With the stakes for successful launches high, and demand for commercial roles increasing, biopharmas must thoughtfully approach not only hiring but also retention. During a BioSpace webinar, experi…
  biospace · 3mo ago
• Webinar: From Clinical to Commercial: Talent Strategies for Biopharma Growth
  This webinar provides an assessment of recent job market activity across biopharma and explores how companies approaching commercial readiness or building out sales and marketing teams can navigate…
  biospace · 3mo ago